Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open Label Phase I Trial to Evaluate the Safety and Effect of HIVconsv Vaccines in Combination With Histone Deacetylase Inhibitor Romidepsin on the Viral Rebound Kinetic After Treatment Interruption in Early Treated HIV-1 Infected Individuals (BCN02-Romi)

Next Previous
X
Search
Trial Profile

An Open Label Phase I Trial to Evaluate the Safety and Effect of HIVconsv Vaccines in Combination With Histone Deacetylase Inhibitor Romidepsin on the Viral Rebound Kinetic After Treatment Interruption in Early Treated HIV-1 Infected Individuals (BCN02-Romi)

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 05 Apr 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs MVA HIV vaccine (Primary) ; Romidepsin (Primary)
  • Indications HIV-1 infections
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Acronyms BCN02-Romi

    • Most Recent Events

    • 22 Feb 2023 Results (n=11) assessing to identify biomarkers associated with virus control during monitored antiretroviral pause, longitudinal proteomics screenings were conducted in plasma from BCN02 participants, presented at the 30th Conference on Retroviruses and Opportunistic Infections 2023.
    • 03 Nov 2021 Results of neurological observational substudy (BCN02-Neuro substudy) (n=11) assessing the central nervous system (CNS) impact of a kick & kill HIV cure strategy using therapeutic vaccine MVA.HIVconsv and the histone deacetylase inhibitor (HDACi) romidepsin (RMD) as latency-reversing agent, published in the AIDS.
    • 04 Jan 2021 New trial record
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top